Wood Larry L

Larry L Wood sold 8,950 shares of Edwards Lifesciences (EW) at $78.06 on 2025-08-18; EW -9.4% annual revenue growth.

Wood sold 8,950 shares, reducing his stake from 215,850 to 206,900 shares (-4.1% of pre-transaction holdings). The sale occurred at $78.06, and the stock currently trades at $78.30, slightly above the transaction price. At the same-ticker level, Wood's prior four measurable sales at EW (from Nov 2023 through Nov 2024) all showed positive 90-day returns ranging from 8.3% to 29.5%, indicating the stock rose after his prior sales—poorly-timed exits from that perspective. However, his cross-ticker track record shows a 38.46% well-timed rate with an average 90-day return of 3.8% post-sale, suggesting modest timing discipline across his broader portfolio activity. Edwards Lifesciences faces headwinds with annual revenue declining 9.4% year-over-year and a modest 11.09 P/E, though the company remains profitable with $333.2M net income on $1.5B quarterly revenue. This transaction alone is routine in scale and pattern, but the company's revenue contraction warrants investor attention.

Global President TAVR & Surgery sold 8,950 shares of Edwards Lifesciences (EW) at $75.23; stock down -4.1% in 30 days, -20.2% from 52-week high.

Wood Larry L sold 8,950 shares on 2025-06-16 at $75.23, reducing his position by 4.1% to 206.9K shares. EW is trading at $74.82, down 4.1% in 30 days and 20.2% below its 52-week high of $93.78. His prior five sales at this ticker have consistently underperformed post-sale: all five showed positive 90-day returns (ranging from +8.3% to +31.4%), meaning the stock rose after each sale, yielding a 0% well-timed rate at this ticker. His cross-ticker track record shows a 38.46% well-timed rate on 13 prior sells, notably above the prior EW performance pattern. The company faces revenue headwinds (-9.4% annual growth) and trades at a modest P/E of 10.49, though it maintains $358M quarterly net income on $1.4B revenue.

Edwards Lifesciences Global President TAVR sold 25,000 shares ($1.6M) on 2024-11-05; stock now -30.2% from 52-week high at $66.69.

Larry L Wood, Global President TAVR & Surg at Edwards Lifesciences, sold 25,000 shares at $65.91 on 2024-11-05, reducing his holdings from 223.5K to 198.5K shares (-11.2%). The stock has declined significantly since the sale, currently trading at $66.69, which is -30.2% from its 52-week high of $95.56. Examining Wood's prior trades at EW, all 5 prior sells generated positive 90-day returns (ranging from +7.9% to +31.4%), meaning the stock rose after each sale—a 0% well-timed rate at the 90-day mark. This current sale deviates from that historical pattern: the stock was already trading near its lows relative to the 52-week range at the time of sale, and has fallen further, suggesting a structurally different market environment than his previous transactions at this ticker.